economics and social security were extracted. The burden was measured for "LBPepisodes", defined as time periods with consecutive visits to the healthcare system with a relevant diagnosis code, continuing until 6 months have elapsed without costs incurred by LBP-related visits. Results: More than 72,000 patients were identified, with over 95,000 LBP-episodes. The average episode length was 56/176 days in episodes without/with surgery. The mean total cost per episode was estimated at € 5,453, where indirect costs constituted 68.4%, medical visits including diagnostic imaging 14.5%, other inpatient care 8.2%, surgery 7.9%, and pharmaceuticals 1.0%. In men/women, the mean total cost per episode was estimated to € 22,174/€ 24,833 in episodes with surgery, and € 4,175/€ 3,957 in episodes without surgery. The total burden of LBP in Sweden in 2012 was estimated at € 704M, with a burden per capita of € 73. Higher age, women, comorbidities, surgery and less education were found to be significant predictors of higher costs. ConClusions: The societal burden of LBP is substantial and varies significantly between different types of patients. It is important to identify periods and interventions within a LBP-episode that can be relevantly adjusted in order to optimize cost-effectiveness of treatment, and also, to realize that results may be dependent on the time frame chosen for a LBPepisode. Acknowledgements: The study was financed with an unrestricted grant from Medtronic.
BackgroundBiobanks for research (BBR) are organized repositories of biological materials and associated health information with enormous potential and value for scientific research. In consonance with increasing attention to healthy aging research, BBR specifically oriented to chronic diseases and aging populations have gathered heightened attention. Public perceptions and patient choices are key to design, develop and implement patient-centered BBR. Public awareness, education and involvement are confidence building and unequivocally lead to higher participation in scientific enterprises.ObjectivesTo assess patient awareness, perception and choices regarding aging biobanking activities.MethodsWe developed and applied a standard anonymous questionnaire to rheumatology terciary outpatients, aged 50 or older, between March-October 2016. Demographic data and perceptions about biobanking were collected. Data analysis was performed using Stata 14® software.ResultsWe obtained a total of 131 valid responses [age (min-max, 50–93), mean (64); sex ratio (M/F) (40/91, 44%), education years (min-max, 0–20), mean (8.5)]. 69% of respondents did not know the specific term “biobank” but 57% were aware about the possibility of donating their biological material for research purposes. Furthermore, 77% of respondents indicated they were willing to contribute with their biological material to BBR, stating they had no particular preference whether these infrastructures were of private or public nature. However, they expressed a clear preference for these to be based at scientific research institutes (50%), instead of hospitals (23%), universities (16%) or biotechnology companies (7%). Moreover, respondents highlighted diferent requirements for their participation with anonymity (31%) and confidentiality (27%) ranking as top priorities. Most importantly, a majority of respondents (70%) expressed their agreement with a biobank exclusively dedicated to the study of aging, considering that people of older ages have higher disease burdens and that such research infrastructures and practices expressed respect for the particular problems of the elderly (Figure).ConclusionsOur study constitutes a comprehensive assessment of public perceptions and patient choices regarding biobanks for aging research purposes among rheumatology outpatients. Although awareness is still suboptimal, BBR are highly regarded health infrastructures with enormous potential for further patient-centered development.Disclosure of InterestNone declared
antiresorptive agents against each other didn't evidence a statistically significant difference. ConClusions: The results of this MTC can suggest that Risedronate, compared to placebo, is expected to provide the highest rate of reduction in NVF in women affected by postmenopausal OP. However, the mixed treatment comparisons among alendronate, risedronate, ibandronate, zolendronate and denosumab did not evidence a statistically significant difference.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.